Over the next three years, it is expected product patent expirations will result in $50 billion in lost revenues. This pressing issue is forcing pharmaceutical companies to reassess the scale and affordability of their sales and marketing organizations. The picture quickly becomes more complex when you add the move toward selling health solutions versus products, the digital revolution and the growth of emerging markets.
Life sciences sales and marketing executives are struggling to keep up with these changes while being asked to reduce as much as 30 percent of their sales and marketing operating costs. The answer to this challenge is a new customer-centered sales and marketing model featuring integrated, end-to-end business managed services for select functions with technology as the driving force.